The research exhibits pirfenidone as a possible multitarget agent towards scarring following glaucoma filtration surgical treatment by establishing the antiangiogenesis impact of it within the wound therapeutic approach phenobarbital will decrease the level or impact of pirfenidone by influencing hepatic enzyme CYP1A2 metabolism. Contraindicated. Use of robust CYP1A2 inducers need https://carlm777alw9.blog4youth.com/profile